Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Strauss

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Journal of Crohn'S & Colitis|June 20, 2018
Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 StudyBruce E Sands, William J Sandborn, Brian G Feagan, et al.
Gastroenterology|June 18, 2013
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitisWilliam J Sandborn, Brian G Feagan, Colleen Marano, et al.
Hepatology (Baltimore, Md.)|November 25, 2015
Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept studyGideon M Hirschfield, M Eric Gershwin, Richard Strauss, et al.
Journal of Comparative Effectiveness Research|February 17, 2023
Using multiple imputation of real-world data to estimate clinical remission in pediatric inflammatory bowel diseaseNanhua Zhang, Chunyan Liu, Steven J Steiner, et al.
Journal of Crohn'S & Colitis|March 17, 2026
Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kgElisabeth De Greef, Dan Turner, Jarosław Kierkuś, et al.
Gastroenterology|June 6, 2013
Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitisWilliam J Sandborn, Brian G Feagan, Colleen Marano, et al.
Investigative Radiology|May 31, 2022
Free-Breathing Low-Field MRI of the Lungs Detects Functional Alterations Associated With Persistent Symptoms After COVID-19 InfectionSimon Lévy, Rafael Heiss, Robert Grimm, et al.
Gastroenterology|July 5, 2011
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitisJean Frédéric Colombel, Paul Rutgeerts, Walter Reinisch, et al.
Gastroenterology|March 14, 2020
Serum Biomarkers Identify Patients Who Will Develop Inflammatory Bowel Diseases Up to 5 Years Before DiagnosisJoana Torres, Francesca Petralia, Takahiro Sato, et al.
Gastroenterology|July 8, 2018
Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative ColitisShannon E Telesco, Carrie Brodmerkel, Hongyan Zhang, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Journal of Crohn'S & Colitis|June 20, 2018
Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 StudyBruce E Sands, William J Sandborn, Brian G Feagan, et al.
Gastroenterology|June 18, 2013
Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitisWilliam J Sandborn, Brian G Feagan, Colleen Marano, et al.
Hepatology (Baltimore, Md.)|November 25, 2015
Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept studyGideon M Hirschfield, M Eric Gershwin, Richard Strauss, et al.
Journal of Comparative Effectiveness Research|February 17, 2023
Using multiple imputation of real-world data to estimate clinical remission in pediatric inflammatory bowel diseaseNanhua Zhang, Chunyan Liu, Steven J Steiner, et al.
Journal of Crohn'S & Colitis|March 17, 2026
Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kgElisabeth De Greef, Dan Turner, Jarosław Kierkuś, et al.
Gastroenterology|June 6, 2013
Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitisWilliam J Sandborn, Brian G Feagan, Colleen Marano, et al.
Investigative Radiology|May 31, 2022
Free-Breathing Low-Field MRI of the Lungs Detects Functional Alterations Associated With Persistent Symptoms After COVID-19 InfectionSimon Lévy, Rafael Heiss, Robert Grimm, et al.
Gastroenterology|July 5, 2011
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitisJean Frédéric Colombel, Paul Rutgeerts, Walter Reinisch, et al.
Gastroenterology|March 14, 2020
Serum Biomarkers Identify Patients Who Will Develop Inflammatory Bowel Diseases Up to 5 Years Before DiagnosisJoana Torres, Francesca Petralia, Takahiro Sato, et al.
Gastroenterology|July 8, 2018
Gene Expression Signature for Prediction of Golimumab Response in a Phase 2a Open-Label Trial of Patients With Ulcerative ColitisShannon E Telesco, Carrie Brodmerkel, Hongyan Zhang, et al.
Pageof 5